C. Max Schmidt
YOU?
Author Swipe
View article: PancreaSeq Genomic Classifier (PancreaSeq GC) Improves Pancreatic Cyst Classification and Detection of Advanced Neoplasia: A Multi-institutional Validation Study
PancreaSeq Genomic Classifier (PancreaSeq GC) Improves Pancreatic Cyst Classification and Detection of Advanced Neoplasia: A Multi-institutional Validation Study Open
Background The preoperative classification of pancreatic cysts and detection of advanced neoplasia (high-grade dysplasia/pancreatic ductal adenocarcinoma [PDAC]) represents a significant diagnostic challenge. A prospective, multi-instituti…
View article: Treatment and Outcomes for Patients With Inadequate Lymphadenectomy After Resection of Stage II Small Bowel Adenocarcinoma
Treatment and Outcomes for Patients With Inadequate Lymphadenectomy After Resection of Stage II Small Bowel Adenocarcinoma Open
Background and Objectives Adjuvant chemotherapy (AC) is considered for patients with stage II small bowel adenocarcinoma (SBA) with an inadequate lymphadenectomy; however, the prognostic role of additional high‐risk features (T4 primary, p…
View article: B-366 Determination of mucinous pancreatic cystic lesion dysplasia grade using a Surface-Enhanced Raman Spectroscopy (SERS)-enabled multi-analyte biomarker panel
B-366 Determination of mucinous pancreatic cystic lesion dysplasia grade using a Surface-Enhanced Raman Spectroscopy (SERS)-enabled multi-analyte biomarker panel Open
Background Pancreatic cystic lesions (PCLs), a subset of which have the potential to develop into pancreatic cancer, are increasingly detected on cross-sectional imaging and pose challenges to clinicians due to the lack of diagnostic tools…
View article: Faster VGGT with Block-Sparse Global Attention
Faster VGGT with Block-Sparse Global Attention Open
Efficient and accurate feed-forward multi-view reconstruction has long been an important task in computer vision. Recent transformer-based models like VGGT and $π^3$ have achieved impressive results with simple architectures, yet they face…
View article: Supplemental Figure S7 from Integrated Metabolomics and Spatial Transcriptomics of Cystic Pancreatic Cancer Precursors Reveals Dysregulated Polyamine Metabolism as a Biomarker of Progression
Supplemental Figure S7 from Integrated Metabolomics and Spatial Transcriptomics of Cystic Pancreatic Cancer Precursors Reveals Dysregulated Polyamine Metabolism as a Biomarker of Progression Open
Supplemental Figure S7. Heatmap illustrating differences in gene-based signatures of immune cell types in epilesional (Epi), juxtalesional (Juxta), and perilesional (Peri) regions of high-grade (HG) and IPMN/PDAC compared to low-grade (LG)…
View article: Supplemental Table S3 from Integrated Metabolomics and Spatial Transcriptomics of Cystic Pancreatic Cancer Precursors Reveals Dysregulated Polyamine Metabolism as a Biomarker of Progression
Supplemental Table S3 from Integrated Metabolomics and Spatial Transcriptomics of Cystic Pancreatic Cancer Precursors Reveals Dysregulated Polyamine Metabolism as a Biomarker of Progression Open
Supplemental Table S3. Predictive performance of individual polyamines for detection of HG and PDAC/IPMN.
View article: Supplemental Figure S2 from Integrated Metabolomics and Spatial Transcriptomics of Cystic Pancreatic Cancer Precursors Reveals Dysregulated Polyamine Metabolism as a Biomarker of Progression
Supplemental Figure S2 from Integrated Metabolomics and Spatial Transcriptomics of Cystic Pancreatic Cancer Precursors Reveals Dysregulated Polyamine Metabolism as a Biomarker of Progression Open
Supplemental Figure S2. Association between cystic fluid and plasma polyamine levels in patients with IPMN.
View article: Supplemental Table S6 from Integrated Metabolomics and Spatial Transcriptomics of Cystic Pancreatic Cancer Precursors Reveals Dysregulated Polyamine Metabolism as a Biomarker of Progression
Supplemental Table S6 from Integrated Metabolomics and Spatial Transcriptomics of Cystic Pancreatic Cancer Precursors Reveals Dysregulated Polyamine Metabolism as a Biomarker of Progression Open
Supplemental Table S6. Patient and tumor characteristics for IPMN samples analyzed by spatial transcriptomics.
View article: Supplemental Table S4 from Integrated Metabolomics and Spatial Transcriptomics of Cystic Pancreatic Cancer Precursors Reveals Dysregulated Polyamine Metabolism as a Biomarker of Progression
Supplemental Table S4 from Integrated Metabolomics and Spatial Transcriptomics of Cystic Pancreatic Cancer Precursors Reveals Dysregulated Polyamine Metabolism as a Biomarker of Progression Open
Supplemental Table S4. Predictive performance of cystic fluid polyamines for differentiating HG IPMN and IPMN/PDAC from LG IPMN among males and females and by pathology.
View article: Supplemental Figure S6 from Integrated Metabolomics and Spatial Transcriptomics of Cystic Pancreatic Cancer Precursors Reveals Dysregulated Polyamine Metabolism as a Biomarker of Progression
Supplemental Figure S6 from Integrated Metabolomics and Spatial Transcriptomics of Cystic Pancreatic Cancer Precursors Reveals Dysregulated Polyamine Metabolism as a Biomarker of Progression Open
Supplemental Figure S6. Box plots demonstrating transcript levels of polyamine metabolizing enzymes in epilesional, juxtalesional, and perilesional areas of PDAC/IPMN, HG IPMN, and LG IPMN.
View article: Data from Integrated Metabolomics and Spatial Transcriptomics of Cystic Pancreatic Cancer Precursors Reveals Dysregulated Polyamine Metabolism as a Biomarker of Progression
Data from Integrated Metabolomics and Spatial Transcriptomics of Cystic Pancreatic Cancer Precursors Reveals Dysregulated Polyamine Metabolism as a Biomarker of Progression Open
Purpose:We conducted metabolomics and spatial cell transcriptomics of intraductal papillary mucinous neoplasms (IPMN), recognized pancreatic cancer precursors, to identify oncometabolites that inform upon risk of malignancy of IPMNs.Experi…
View article: Supplemental Table S2 from Integrated Metabolomics and Spatial Transcriptomics of Cystic Pancreatic Cancer Precursors Reveals Dysregulated Polyamine Metabolism as a Biomarker of Progression
Supplemental Table S2 from Integrated Metabolomics and Spatial Transcriptomics of Cystic Pancreatic Cancer Precursors Reveals Dysregulated Polyamine Metabolism as a Biomarker of Progression Open
Supplemental Table S2. Metabolites detected and quantified in cystic fluid of patients with IPMN.
View article: Supplemental Figure S4 from Integrated Metabolomics and Spatial Transcriptomics of Cystic Pancreatic Cancer Precursors Reveals Dysregulated Polyamine Metabolism as a Biomarker of Progression
Supplemental Figure S4 from Integrated Metabolomics and Spatial Transcriptomics of Cystic Pancreatic Cancer Precursors Reveals Dysregulated Polyamine Metabolism as a Biomarker of Progression Open
Supplemental Figure S4. Scatter plots illustrating associations between cystic fluid spermidine, spermine, diacetylspermidine (DiAcSpmd), and acetylcadaverine (AcCad) [y-axis] and CA19-9 [x-axis].
View article: Supplemental Figure S9 from Integrated Metabolomics and Spatial Transcriptomics of Cystic Pancreatic Cancer Precursors Reveals Dysregulated Polyamine Metabolism as a Biomarker of Progression
Supplemental Figure S9 from Integrated Metabolomics and Spatial Transcriptomics of Cystic Pancreatic Cancer Precursors Reveals Dysregulated Polyamine Metabolism as a Biomarker of Progression Open
Supplemental Figure S9. Association between macrophages and polyamine metabolism.
View article: Supplemental Figure S5 from Integrated Metabolomics and Spatial Transcriptomics of Cystic Pancreatic Cancer Precursors Reveals Dysregulated Polyamine Metabolism as a Biomarker of Progression
Supplemental Figure S5 from Integrated Metabolomics and Spatial Transcriptomics of Cystic Pancreatic Cancer Precursors Reveals Dysregulated Polyamine Metabolism as a Biomarker of Progression Open
Supplemental Figure S5. Polyamine levels in human resected IPMN tissues and in cell extracts and conditioned media from doxycycline-activated mutant Kras;Gnas IPMN cell lines.
View article: Supplemental Table S1 from Integrated Metabolomics and Spatial Transcriptomics of Cystic Pancreatic Cancer Precursors Reveals Dysregulated Polyamine Metabolism as a Biomarker of Progression
Supplemental Table S1 from Integrated Metabolomics and Spatial Transcriptomics of Cystic Pancreatic Cancer Precursors Reveals Dysregulated Polyamine Metabolism as a Biomarker of Progression Open
Supplemental Table S1. Patient and tumor characteristics for IPMN Tissues.
View article: Supplemental Figure S1 from Integrated Metabolomics and Spatial Transcriptomics of Cystic Pancreatic Cancer Precursors Reveals Dysregulated Polyamine Metabolism as a Biomarker of Progression
Supplemental Figure S1 from Integrated Metabolomics and Spatial Transcriptomics of Cystic Pancreatic Cancer Precursors Reveals Dysregulated Polyamine Metabolism as a Biomarker of Progression Open
Supplemental Figure S1. Spearman correlation heatmap illustrating association between acetylated polyamine levels in cystic fluid of patients with IPMN.
View article: Supplemental Table S5 from Integrated Metabolomics and Spatial Transcriptomics of Cystic Pancreatic Cancer Precursors Reveals Dysregulated Polyamine Metabolism as a Biomarker of Progression
Supplemental Table S5 from Integrated Metabolomics and Spatial Transcriptomics of Cystic Pancreatic Cancer Precursors Reveals Dysregulated Polyamine Metabolism as a Biomarker of Progression Open
Supplemental Table S5. Absolute concentrations (nM) of polyamines and acetylated derivatives in cystic fluid.
View article: Supplemental Figure S3 from Integrated Metabolomics and Spatial Transcriptomics of Cystic Pancreatic Cancer Precursors Reveals Dysregulated Polyamine Metabolism as a Biomarker of Progression
Supplemental Figure S3 from Integrated Metabolomics and Spatial Transcriptomics of Cystic Pancreatic Cancer Precursors Reveals Dysregulated Polyamine Metabolism as a Biomarker of Progression Open
Supplemental Figure S3. Levels of CA19-9 in cystic fluid of patients with IPMN.
View article: Supplemental Figure S8 from Integrated Metabolomics and Spatial Transcriptomics of Cystic Pancreatic Cancer Precursors Reveals Dysregulated Polyamine Metabolism as a Biomarker of Progression
Supplemental Figure S8 from Integrated Metabolomics and Spatial Transcriptomics of Cystic Pancreatic Cancer Precursors Reveals Dysregulated Polyamine Metabolism as a Biomarker of Progression Open
Supplemental Figure S8. Relationship between PME transcript levels and immune subtypes in IPMN tissues.
View article: Artificial Intelligence in Pancreatic Intraductal Papillary Mucinous Neoplasm Imaging: A Systematic Review
Artificial Intelligence in Pancreatic Intraductal Papillary Mucinous Neoplasm Imaging: A Systematic Review Open
Background Based on the Fukuoka and Kyoto international consensus guidelines, the current clinical management of intraductal papillary mucinous neoplasm (IPMN) largely depends on imaging features. While these criteria are highly sensitive …
View article: Characterization of the Biochemical Activity of Ktx-1001, a Selective Small Molecule NSD2 Inhibitor, in Surface Plasmon Resonance (SPR)
Characterization of the Biochemical Activity of Ktx-1001, a Selective Small Molecule NSD2 Inhibitor, in Surface Plasmon Resonance (SPR) Open
Background: NSD2 (Nuclear Receptor Binding SET Domain Protein 2), also known as MMSET (Multiple Myeloma SET Domain-Containing Protein) is a Histone Lysine-Methyl Transferase (HMT) that specifically produces mono- and di-methylated histone …
View article: Look Gauss, No Pose: Novel View Synthesis using Gaussian Splatting without Accurate Pose Initialization
Look Gauss, No Pose: Novel View Synthesis using Gaussian Splatting without Accurate Pose Initialization Open
3D Gaussian Splatting has recently emerged as a powerful tool for fast and accurate novel-view synthesis from a set of posed input images. However, like most novel-view synthesis approaches, it relies on accurate camera pose information, l…
View article: Table S7 from Spatial Transcriptomics of Intraductal Papillary Mucinous Neoplasms of The Pancreas Identifies NKX6-2 as a Driver of Gastric Differentiation and Indolent Biological Potential
Table S7 from Spatial Transcriptomics of Intraductal Papillary Mucinous Neoplasms of The Pancreas Identifies NKX6-2 as a Driver of Gastric Differentiation and Indolent Biological Potential Open
Differentially expressed genes between LG, HG, and PDAC samples per region.
View article: Table S4 from Spatial Transcriptomics of Intraductal Papillary Mucinous Neoplasms of The Pancreas Identifies NKX6-2 as a Driver of Gastric Differentiation and Indolent Biological Potential
Table S4 from Spatial Transcriptomics of Intraductal Papillary Mucinous Neoplasms of The Pancreas Identifies NKX6-2 as a Driver of Gastric Differentiation and Indolent Biological Potential Open
Differentially expressed genes between LG and HGPDAC epilesional spots.
View article: Table S15 from Spatial Transcriptomics of Intraductal Papillary Mucinous Neoplasms of The Pancreas Identifies NKX6-2 as a Driver of Gastric Differentiation and Indolent Biological Potential
Table S15 from Spatial Transcriptomics of Intraductal Papillary Mucinous Neoplasms of The Pancreas Identifies NKX6-2 as a Driver of Gastric Differentiation and Indolent Biological Potential Open
Predicted NKX6-2 targets and transcription factors associated with NKX6-2 expression evaluated by GENIE3.
View article: Table S22 from Spatial Transcriptomics of Intraductal Papillary Mucinous Neoplasms of The Pancreas Identifies NKX6-2 as a Driver of Gastric Differentiation and Indolent Biological Potential
Table S22 from Spatial Transcriptomics of Intraductal Papillary Mucinous Neoplasms of The Pancreas Identifies NKX6-2 as a Driver of Gastric Differentiation and Indolent Biological Potential Open
Differentially expressed genes between NKX6-2 overexpressing and control KPC cell lines.
View article: Table S17 from Spatial Transcriptomics of Intraductal Papillary Mucinous Neoplasms of The Pancreas Identifies NKX6-2 as a Driver of Gastric Differentiation and Indolent Biological Potential
Table S17 from Spatial Transcriptomics of Intraductal Papillary Mucinous Neoplasms of The Pancreas Identifies NKX6-2 as a Driver of Gastric Differentiation and Indolent Biological Potential Open
Markers per clusters generated from ST analyses of two pancreas specimens collected from Kras;Gnas mice.
View article: Table S13 from Spatial Transcriptomics of Intraductal Papillary Mucinous Neoplasms of The Pancreas Identifies NKX6-2 as a Driver of Gastric Differentiation and Indolent Biological Potential
Table S13 from Spatial Transcriptomics of Intraductal Papillary Mucinous Neoplasms of The Pancreas Identifies NKX6-2 as a Driver of Gastric Differentiation and Indolent Biological Potential Open
Correlation between percentage of NKX6-2 positive nuclei and GATA-6, MUC5AC, TFF1, and VIM protein expression.